Trial reportBreast cancer research and treatment2026
Effects of a sensorimotor-based, movement quality-focused intervention on functional mobility in breast cancer survivors: a multicenter randomized controlled trial.
Trial report in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comment on "Effects of a sensorimotor-based, movement quality-focused intervention on functional mobility in breast cancer survivors: a multicenter randomized controlled trial".Breast cancer research and treatment · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeBreast cancer survivors frequently experience reductions in physical capacity and sensorimotor impairments following treatment. However, improvements in strength and endurance do not always translate into improvements in functional mobility and balance-related outcomes. This study evaluated whether a sensorimotor-based rehabilitation program emphasizing movement control (Rehabilitation through Movement and Perception, ReMAP) could improve functional mobility and postural stability in breast cancer survivors.
methodsIn this multicenter randomized wait-list controlled trial, 71 breast cancer survivors (mean age 50.7 ± 8.9 years) with mild functional impairment who had completed curative breast cancer treatment at least 3 months prior to enrollment were assigned to a ReMAP intervention group (n = 41) or a wait-list control group (n = 30). The 8-week intervention consisted of supervised, low- to moderate-intensity sensorimotor exercises targeting postural alignment, coordination, and balance. Functional mobility was assessed using the Timed Up and Go (TUG) test. Secondary outcomes included handgrip strength and 6-min walk distance as indicators of physical capacity, disability assessed using the World Health Organization Disability Assessment Schedule (WHODAS 12), and postural stability quantified by kinematic measures of center-of-mass sway.
resultsParticipants in the ReMAP group demonstrated a significantly greater improvement in functional mobility than controls, with a larger reduction in TUG time at 8 weeks (group × time interaction: β = - 0.97 s, 95% CI 1.93 to - 0.01; p = 0.049). Postural stability improved significantly, as evidenced by reductions in mediolateral and anteroposterior center-of-mass sway. No significant between-group differences were observed in handgrip strength, 6-min walk distance, or self-reported disability. Exploratory analyses suggested that improvements in TUG performance were more closely associated with changes in movement quality than with changes in physical capacity.
conclusionsA sensorimotor-based rehabilitation program improved functional mobility and postural stability in breast cancer survivors with relatively preserved physical capacity. Targeting movement quality may address key mechanisms underlying balance-related vulnerability in survivorship care.
Indexed as
Identifiers
41874709What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.